Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 9Ovarian Neoplasms 5Carcinoma, Non-Small-Cell Lung 3Pancreatic Neoplasms 2Multiple Myeloma 2Stomach Neoplasms 1Osteosarcoma 1Neuroblastoma 1Neoplasms by Site 1Neoplasm Metastasis 1Lung Neoplasms 1Head and Neck Neoplasms 1Gastrointestinal Neoplasms 1Digestive System Neoplasms 1Colorectal Neoplasms 1Bites and Stings 1Adenocarcinoma 1

Interventions

Gemcitabine 6Irinotecan 4130-nm albumin-bound paclitaxel 4Cisplatin 3Albumin-Bound Paclitaxel 3napabucasin 2Leucovorin 2Imatinib Mesylate 2Everolimus 2Ascorbic Acid 2spartalizumab 1pralsetinib 1pembrolizumab 1dostarlimab 1copanlisib 1alectinib 1Ramucirumab 1Paclitaxel 1NUC-1031 1Levoleucovorin 1KRN-330 1HhAntag691 1Fluorouracil 1Cyclophosphamide 1Capecitabine 1Bevacizumab 15,10-methylenetetrahydrofolic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Digestive System Neoplasms × dostarlimab × Clear all
NCT05980416 2025-11-14

Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2

Elevation Oncology

Phase 1 Terminated
88 enrolled 18 charts
Gastrointestinal

Adenocarcinoma, Digestive System Neoplasms, Gastrointestinal Neoplasms, Neoplasms, Neoplasms by Site, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡